Novavax Balance Sheet
NASDAQ: NVAXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Novavax financial position
At the end of fiscal 2025, Novavax reported total assets of $1.18 billion, down 24.6% from a year earlier against total liabilities of $1.30 billion. Shareholders' equity was negative at -$127.8 million, meaning liabilities exceed assets; this is often the result of large share buybacks or accumulated losses. The company held $240.6 million in cash and equivalents against $244.2 million of debt, a net debt position of $3.6 million.
The current ratio (current assets divided by current liabilities) was 2.13, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Novavax balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 240.63M | 530.23M | 568.50M | 1.34B | 1.52B | 553.40M | 78.82M | 70.15M | 106.31M | 144.35M |
| Short-Term Investments | 494.45M | 392.89M | 0 | — | 0 | 157.65M | 0 | 21.98M | 51.00M | 91.13M |
| Receivables | — | — | — | — | 454.99M | 262.01M | 7.50M | — | — | 233.00K |
| Inventory | 11.54M | 8.75M | 41.70M | 36.68M | 8.87M | — | — | — | — | — |
| Total Current Assets | 978.28M | 1.13B | 1.14B | 1.70B | 2.16B | 1.25B | 97.25M | 119.28M | 203.31M | 287.83M |
| Property, Plant & Equipment | 44.80M | 138.41M | 305.77M | 294.25M | 225.74M | 179.95M | 11.45M | 28.43M | 35.99M | 40.18M |
| Goodwill | 113.46M | 107.48M | 127.45M | 126.33M | 131.48M | 135.38M | 51.15M | 51.97M | 53.56M | 51.67M |
| Intangible Assets | — | — | — | — | 4.77M | 5.72M | 5.58M | 6.54M | 7.87M | 9.22M |
| Total Assets | 1.18B | 1.56B | 1.80B | 2.26B | 2.58B | 1.58B | 172.96M | 207.98M | 302.49M | 394.30M |
| Accounts Payable | 24.58M | 41.58M | 132.61M | 216.52M | 127.05M | 54.33M | 2.91M | 9.30M | 5.61M | 5.68M |
| Total Current Liabilities | 459.95M | 1.15B | 1.64B | 2.46B | 2.39B | 579.67M | 25.80M | 45.54M | 73.67M | 66.41M |
| Long-Term Debt | 244.21M | — | — | — | — | — | — | — | — | — |
| Total Liabilities | 1.30B | 2.18B | 2.51B | 2.89B | 2.93B | 955.27M | 358.97M | 375.91M | 404.23M | 399.85M |
| Shareholders' Equity | -127.75M | -623.84M | -716.93M | -634.08M | -351.67M | 627.21M | -186.02M | -167.94M | -101.73M | -5.55M |
| Retained Earnings | -4.57B | -5.01B | -4.82B | -4.28B | -3.62B | -1.87B | -1.43B | -1.30B | -1.11B | -930.00M |
| Total Debt | 244.21M | — | — | — | — | — | — | — | — | — |
| Net Cash (Debt) | 490.87M | 923.12M | 568.50M | 1.34B | 1.52B | 711.05M | 78.82M | 92.13M | 157.30M | 235.48M |
| Shares Outstanding | 162.58M | 160.42M | 139.51M | 86.04M | 75.84M | 70.95M | 32.35M | 19.22M | 323.23M | 271.25M |
This table shows 10 annual periods of Novavax's balance sheet, from FY 2025 back to FY 2016, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow NVAX's reporting calendar. What is a balance sheet?